High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions

HIV-1-infectionHypovitaminosis D

Interventions

OTHER

placebo Oil

participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4

DRUG

25-Hydroxyvitamin D

Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4

Trial Locations (2)

Govt Said Mitha Teaching Hospital Lahore, Lahore

Fatima Majeed, Lahore

All Listed Sponsors

collaborator

The National HIV/AIDS Programme

OTHER_GOV

lead

University of the Punjab

OTHER

NCT05306704 - High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial | Biotech Hunter | Biotech Hunter